GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (XSWX:BMY) » Definitions » Cyclically Adjusted Revenue per Share

Bristol-Myers Squibb Co (XSWX:BMY) Cyclically Adjusted Revenue per Share : CHF0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted revenue per share for the three months ended in Mar. 2024 was CHF4.747. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Bristol-Myers Squibb Co's average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bristol-Myers Squibb Co was 10.70% per year. The lowest was -1.00% per year. And the median was 3.90% per year.

As of today (2024-05-25), Bristol-Myers Squibb Co's current stock price is CHF44.39. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was CHF0.00. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 7.00. The lowest was 2.21. And the median was 4.69.


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.70 9.51 - - -

Bristol-Myers Squibb Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.



Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.747/131.7762*131.7762
=4.747

Current CPI (Mar. 2024) = 131.7762.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.087 100.560 2.735
201409 2.200 100.428 2.887
201412 2.478 99.070 3.296
201503 2.362 99.621 3.124
201506 2.328 100.684 3.047
201509 2.358 100.392 3.095
201512 2.532 99.792 3.344
201603 2.564 100.470 3.363
201606 2.813 101.688 3.645
201609 2.853 101.861 3.691
201612 3.176 101.863 4.109
201703 2.954 102.862 3.784
201706 3.018 103.349 3.848
201709 3.074 104.136 3.890
201712 3.273 104.011 4.147
201803 3.002 105.290 3.757
201806 3.452 106.317 4.279
201809 3.368 106.507 4.167
201812 3.619 105.998 4.499
201903 3.618 107.251 4.445
201906 3.786 108.070 4.617
201909 3.642 108.329 4.430
201912 4.024 108.420 4.891
202003 4.580 108.902 5.542
202006 4.258 108.767 5.159
202009 4.211 109.815 5.053
202012 4.366 109.897 5.235
202103 4.636 111.754 5.467
202106 4.783 114.631 5.498
202109 4.830 115.734 5.499
202112 4.970 117.630 5.568
202203 4.874 121.301 5.295
202206 5.193 125.017 5.474
202209 4.916 125.227 5.173
202212 4.784 125.222 5.034
202303 4.724 127.348 4.888
202306 4.551 128.729 4.659
202309 4.442 129.860 4.508
202312 4.469 129.419 4.550
202403 4.747 131.776 4.747

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Bristol-Myers Squibb Co  (XSWX:BMY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 7.00. The lowest was 2.21. And the median was 4.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (XSWX:BMY) Business Description

Industry
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.